DEVICE, SYSTEMS, AND METHODS FOR PREVENTION OF DEEP VEIN THROMBOSIS

Abstract

Embodiments provide devices, systems and methods for preventing deep vein (DV) thrombosis (DVT). One embodiment provides a DVT prevention device including a cuff that fits over a patient's knee, an applanator coupled to an inside cuff surface, an expandable member (EM) coupled to the applanator, a pressure source fluidically coupled to the EM and a controller for controlling EM inflation. When the EM is inflated, it applies a force to the applanator which is transmitted to the knee back surface causing a popliteal vein (PV) under the cuff to be compressed so as to increase backpressure behind the compressed PV and subsequently increase the velocity of blood flow in the leg DV's when the EM is deflated. The EM can be inflated in a cycle including pulsed inflation, inflation hold and relaxation. The cycles can be repeated and adjusted to achieve a desired increase of blood flow/velocity in leg DV's.

Claims

1. A device for preventing deep vein thrombosis (DVT) in a patient, the device comprising: a cuff configured to fit over the patient's knee; an applanator coupled to an inside surface of the cuff and located on the cuff so as to be positioned over a back surface of the knee when the cuff is pulled over the knee, the applanator comprising a rigid material and having a tissue contacting surface having a curved shape sized and configured to apply pressure to a back surface of the knee to compress a popliteal vein in a back of the knee when a force is applied to the applanator without damaging a venous valve in the compressed popliteal vein; an expandable member-coupled to the applanator for applying a force to the applanator; a pressure source fluidically coupled to the expandable member and coupled to the cuff; wherein when the expandable member is expanded it applies a force to the applanator which is transmitted by the tissue contacting surface of the applanator to the back surface of the knee and causes the popliteal vein to be compressed so as to minimize blood flow through the popliteal vein without damaging a venous valve in the compressed popliteal vein; and wherein the entire device is configured to be worn on the patient's knee and function while the patient is ambulatory.

2. The DVT prevention device of claim 1, wherein the cuff comprises an elastic or elastomeric material configured to stretch to fit over the patient's knee and then contract to hold the cuff in place.

3. The DVT prevention device of claim 1, wherein the cuff includes a fastening means to allow the cuff to be wrapped around the patient's knee and then fastened to itself using the fastening means.

4. The DVT prevention device of claim 3, wherein the fastening means comprise hooks and fasteners, the hooks positioned on a first portion of the cuff and the fasteners positioned on a second portion of the cuff.

5. The DVT prevention device of claim 1, wherein the expandable member is an expandable balloon.

6. The DVT prevention device of claim 1, wherein the pressure source is a pump, a pneumatic pump or a mechanical pump.

7. The DVT prevention device of claim 1, further comprising a pressure sensor fluidically coupled to at least one of the expandable member or the pressure source for measuring a pressure in the expandable member.

8. The DVT prevention device of claim 1, further comprising a valve fluidically coupled to the expandable member for maintaining and/or releasing pressure in the expandable member.

9. A method for preventing deep vein thrombosis (DVT) in a patient, the method comprising: applying force from an applanator comprising a rigid material to a back surface of the patient's knee to compress a popliteal vein in along the back surface of the knee so as to minimize blood flow through the popliteal vein without damaging a venous valve in the compressed popliteal vein, wherein the force is applied in a compression cycle comprising: i) a pulse period comprising a series of force pulses with intervals of relaxation between the pulses; ii) a hold period of constant force application; and iii) a relaxation period of minimal or no force application; and wherein upon completion of the cycle, a blood velocity within a deep vein of the patient's leg remains elevated for an extended period of time by at least about 100% compared to a blood velocity in the deep vein of the leg prior to force application.

10. The method of claim 9, wherein the applanator applies 0.5 to ten pounds of force to the back surface of the knee.

11. The method of claim 9, where the applanator is positioned on an inside surface of a cuff, the method further comprising: positioning the cuff over a portion of the patient's knee, such that the applanator is positioned over the back portion of the patient's knee to compress the popliteal vein.

12. The method of claim 9, wherein the pulse period is in a range from about 1 to 20 seconds.

13. The method of claim 9, wherein the relaxation period in each compression cycle is in a range from about 1 to 20 seconds.

14. The method of claim 9, where the hold period is in range from about one to five minutes.

15. The method of claim 9, where the series of force pulses comprises five pulses.

16. The method of claim 9, further comprising: repeating the compression cycle.

17. The method of claim 16, wherein the compression cycle is repeated at least twice.

18. The DVT prevention device of claim 1, wherein the applanator is structured to be pivotally advanced against tissue of the back of the patient's knee when the expandable member is expanded.

19. The DVT prevention device of claim 1, wherein the curved surface of the applanator has a diameter in a range from about one to three times a diameter of the patient's popliteal vein.

20. The method of claim 9, wherein the extended period is at least about 15 minutes.

21. The method of claim 9, wherein the extended period is up to about an hour.

22. The method of claim 9, wherein the blood velocity is elevated in a range from about 484 to 506%.

23. The method of claim 9, wherein the blood velocity is elevated in a range from about 355 to 633%.

24. The method of claim 9, wherein the deep vein of the patient's leg is the femoral vein.

25. The method of claim 9, where a parameter of the pressure cycle is adjusted to optimize an increase in deep vein flow velocity for an individual patient.

26. The method of claim 25, wherein the parameter of the pressure cycle is at least one of a force pulse duration, duration between pulses or hold time.

27. The method of claim 25, wherein the force is applied by the applanator is generated by an expandable member coupled to the applanator and the parameter of the pressure cycle is an inflation pressure of the expandable member.

28. The method of claim 25, wherein the parameter of the pressure cycle is adjusted based on a patient hemodynamic parameter.

29. The method of claim 28, wherein the hemodynamic parameter is an average or peak blood velocity in a selected vein, blood pressure or pule rate.

30. The method of claim 29, wherein the selected vein is the femoral vein.

31. The method of claim 25, wherein the parameter of the pressure cycle is adjusted based on a patient activity level.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0040] FIG. 1 is a schematic view illustrating an embodiment of deep vein thrombosis prevention device and system

[0041] FIG. 2 is a cross sectional view of an embodiment of the deep vein thrombosis prevention device

[0042] FIG. 3a is a perspective view of an embodiment of the deep vein thrombosis prevention device showing the applanator in a non deployed state.

[0043] FIG. 3b is a perspective view of an embodiment of the deep vein thrombosis prevention device showing the applanator in the deployed state.

[0044] FIG. 4a is an axial view of the knee area with DVT prevention device positioned around the knee showing the device in the non deployed date.

[0045] FIG. 4b is an axial view of the knee area with DVT prevention device positioned around the knee showing the device in the deployed date with applanator pressing against tissue to flatten/compress and close the popliteal vein.

[0046] FIGS. 5a and 5b are value vs time graphs showing, in FIG. 5a, an embodiment of the pressure cycle; and in FIG. 5b, a generalized resulting increase in common femoral vein peak velocity.

[0047] FIGS. 5c and 5d are pressure vs time graphs depicting different waveforms for the pressure pulses used in a pressure cycle; FIG. 5c depicts a pressure pulse having a square wave shape while FIG. 5d depicts a pressure pulse having a sine wave shape.

[0048] FIGS. 6a and 6b are value vs time graphs showing in FIG. 6a an embodiment of the pressure cycle and in FIG. 6b, the resulting increase in common femoral vein velocity for a particular individual whose common femoral vein velocity was measured.

DETAILED DESCRIPTION OF THE INVENTION

[0049] Various embodiments of the invention provide devices, systems and methods for the prevention of deep vein thrombosis (DVT) in the appendages such as the arms and the legs. Many embodiments provide devices, systems and methods for prevention of deep vein thrombosis (DVT) in the veins of the leg including for example the femoral, popliteal or tibial veins. Particular embodiments provide a DVT prevention (DVTP) device configured to fit over the knee of a patient so as to prevent DVTs in one or more of one or more of the distal common femoral vein, popliteal vein, posterior tibial vein, anterior tibial vein and peroneal vein. With regard to nomenclature, as used herein the term “prevent” (and related terms prevention or preventing) means one or more of the following: reduce the likelihood of the occurrence of a medical condition or event (e.g., deep vein thrombosis), reduce the number of occurrences of a medical condition or event, reduce a severity of a medical condition or event; or reduce the duration of a medical condition or event. Such medical conditions or events may include without limitation, vascular thrombosis, venous thrombosis and deep vein thrombosis and related conditions or events such as an embolism, pulmonary embolism and cerebral embolism, ischemia and edema. Also, the term “about” means within 10% of a stated value including those for a measurement, characteristic, parameter or property and more preferably within 5% of such a stated value. Similarly, the term “substantially” means with 10% of a stated property, condition, or state, and more preferably within 5% of a such a property, condition or state.

[0050] Referring now to FIGS. 1-6, an embodiment of a deep vein thrombosis prevention device 10 can comprise a cuff 20, an applanator 30, an expansion device 40 such as an expandable balloon or other expandable member, a pressure source 50 and a controller 60. The applanator 30 is typically coupled to an inside surface 25 of the cuff. The balloon or other expandable member 40 is positioned between applanator 30 and a hinge plate 71 described herein. The pressure source 50 is fluidically coupled to the expandable member 40.

[0051] FIGS. 4a and 4b are axial views illustrating use of the device 10 to compress the popliteal vein PV or other deep vein DV. The figures show the cuff wrapped around the knee area KA with the balloon in the inflated/non deployed date (FIG. 4a) and in the deployed state (FIG. 4b). When the balloon or other expandable member 40 is expanded, it applies a force to the applanator 30 which is transmitted by the tissue contacting surface 35 of the applanator as force/pressure to the surface of the leg (in this case posterior portion PP of the knee) which causes the deep vein DV such as the popliteal vein PV to be flattened or otherwise compressed so as to minimize blood flow through the deep vein DV. When the expandable balloon 40 is deflated, the pressure applied from the applanator to the leg is ceased and the vein expands with resumption of blood flow.

[0052] Cuff 20 is desirably sufficiently elastic to be pulled over and positioned over a desired area of the user's leg L such as the knee area KA. Accordingly, it may comprise various elastomers known in the polymer arts such as silicone, polyurethane and the like. In additional or alternative embodiments, the cuff 20 can be configured to be wrapped over and around the leg L (or other appendage such as the arm) and then held in place by a fastening means 28. In various embodiments, fastening means 28 may correspond to one or more of VELCRO, a clamp, a clip, a band, a strap or other fastener known in the art.

[0053] The applanator 30 is configured to apply a force to the outer surface of the leg such as that behind the knee (e.g., so as to flatten or otherwise compress a selected deep vein DV to as to interdentally substantially stop or reduce blood flow through the leg. Thus, as used herein, the term “applanator” means a device or structure for applying force to an external tissue surface of the body to flatten or otherwise compress a vein beneath the tissue surface, typically, a deep vein. Embodiments of the applanator 30 have a tissue contacting surface 35 having a curved or other shape 39 configured to apply force (per unit area) to a surface of the leg sufficient to compress a deep vein in the leg such as the popliteal vein. Typically, that shape 39 will be semicircular or other convex shape. The force may be in the range of about 0.5 to ten pounds with specific embodiments of 1, 2, 3, 5, 6, 7, 8 and 9 pounds. Accordingly, the applanator 30 will desirably be fabricated from material having sufficient rigidity to apply such a force. Suitable materials include various thermoset polymers known in the art as well as rigid metals. Typically, the tissue contacting surface 35 of the applanator will have a semi-circular shape so as to concentrate force on the center or other area of the leg containing the selected deep vein. In the case of the popliteal vein PV, the applanator diameter 38 is configured to concentrate force between the medial and lateral gastrocnemius muscle and tendons where the PV lies. Accordingly, in such embodiments the diameter 38 of the tissue contacting surface 35 may also correspond to approximately the distance between the lateral and medial gastrocnemius tendons/ligaments on either side of the popliteal vein or divisor thereof such as half, a third or quarter of that distance. In various embodiments, the applanator 30 may be custom fit to an individual patient (e.g., based on these or other measurements depending upon the area to be treated) and/or be custom fabricated using 3D printing methods. Also, the applanator 30 is desirably positioned on the cuff to be centered over the selected deep vein to be compressed. In the case of the popliteal vein, this corresponds approximately to center of the back of the knee.

[0054] The applanator 30 will typically include a base portion 36 having a rectangular or square shape and the curved tissue contacting portion 35 which is attached or integral to the base portion. As described above, the tissue contacting portion 35 of applanator 30 will typically have a semi-circular or other convex shape with the convex portion making contact with tissue. In many embodiments, the base portion 36 of the applanator is attached to a hinge 70 including a hinge plate 71 (also known as a base portion 71) which is in either directly or indirectly attached to cuff 20. The hinge 70 also includes a hinge element 77 on one side of the plate 71 which engages a corresponding hinge element 37 on the applanator 30 allowing the applanator to pivot up into tissue when the balloon or other expandable member 40 is inflated, as shown in FIGS. 3A and 3B. The base portion 71 of the hinge 70 may have an indented portion 75 in its center area which has a contour approximating at least a portion of that of the balloon so as to hold the balloon 40 in place when the balloon is inflated. Also, desirably as described below with respect to the support structure, the hinge plate has sufficient rigidity such that it does not appreciable deform upon inflation of the balloon and mechanically perform in similar way as to the support structure to prevent expansion of cuff 20 and direct the balloon inflation forces to applanator 30 and in turn to the underlying tissue to be compressed by the applanator.

[0055] According to one or more embodiments, the DVT device 10 may also include a support structure 80 attached to cuff 20 and positioned between the cuff and the hinge plate 71 as is shown in FIGS. 3a and 3b. The support structure 80 is mechanically structured, e.g. in terms of its shape and rigidity to direct force generated by the balloon or other expansion device 40 inward onto the applanator 30 rather than have it be dissipated by causing expansion of the cuff 20. Desirably, the support structure 80 is made of sufficiently rigid materials such as thermoset plastic or metal which do not deform when the balloon is inflated.

[0056] In particular embodiments, the support structure 80 may comprise a flat surface or comprise two portions: an indented portion and a larger flat portion which surrounds the indented flat portion (which are not shown but which may generally correspond to the base 71 (e.g., a hinge plate) and contour portions 75 of hinge 70. Similar to the hinge plate, the indented portion may have a contour corresponding to at least a portion of that of the inflated balloon so as to partially hold the balloon when the balloon is inflated. The larger flat portion serves to distribute the forces from the balloon expansion of a larger area of the cuff so as to reduce the pressure on the cuff and thus the amount of cuff expansion resulting from balloon inflation. This in turn reduces the dissipation of the forces from balloon expansion by having them cause expansion of the cuff or release of the VELCRO fastening portions on the cuff. In turn, this results in a greater amount of the force of balloon expansion being transferred to the applanator 40 and in turn to the tissue surface to cause compression/flattening of selected deep vein beneath the applanator such as the popliteal vein. Such embodiments are particularly useful for embodiments of an elastic cuff or those where the cuff uses VELCRO fastening portions which may become unfastened by the application of force from the expanding balloon. Also desirably, the support structure flat portion has a larger surface area than the overlying hinge plate so as to provide further mechanical opposition to the forces from the balloon expansion tending to cause cuff expansion as well distribute those forces over a larger area of the cuff thus reducing the amount and likelihood of cuff expansion.

[0057] Expansion device 40 will typically correspond to various expandable balloons or other expandable members known in the medical device arts including the balloon catheter arts. For ease of discussion, expansion device 40 will now be referred to as either expandable member 40 or balloon 40. According to various embodiments, the expandable balloon 40 may be fabricated from one of various expandable balloon materials known in the medical arts including for example, silicone, polyurethane, and copolymers thereof. In preferred embodiments the expandable balloon or other expandable member is made of relatively non-compliant materials such as PET, polyethylene (e.g., HDPE), irradiated polyethylene (e.g., via ebeam technology) and other polymers and copolymers thereof such that the balloon is able hold a fixed expanded shape and apply force to the applanator rather than continue to expand outward beyond its inflated shape. In alternative or additional embodiments, the expansion device may comprise an electric-mechanically based expansion device including for example, a piezoelectric material-based device, a solenoid, an electric motor or the like. For embodiments using an electro-mechanically based device, a pressure source is not required merely an electric power source such as portable batteries known in art for example alkaline or lithium ion batteries.

[0058] The pressure source 50 will typically correspond to a pump 51 such as a pneumatic pump which can be fluidically connected to balloon 40 by means of pneumatic hose or tubing or connector 55. The pump is selected and configured to generate sufficient pressure for the expandable member to apply sufficient compressive force from the applanator to a target tissue surface flatten/compress a selected deep vein beneath the tissue surface as described herein. The generated pressure may be in the range of about 0.5 to 20 atms, with specific embodiments of 2, 5, 7, 10 and 15 atms. Higher ranges are also contemplated. In various embodiments, the pressure source may correspond to a pneumatic or mechanical pump. In alternative or additional embodiments, the pressure source 50 may correspond to a compressed gas source containing compressed air or an inert gas. In various embodiments, pump 51 (or other pressure source 50) and/or tubing or other connections 55 to balloon 40 may be acoustically insulated with acoustical insulation 52 or other otherwise acoustically dampened so that the inflation of balloon 40 or other expandable member 40 is relatively quite and/or imperceptible to the user. One configuration of such acoustical insulation 52 positioned around pump 51 is shown in FIG. 1. In various embodiments, acoustical insulation 52 may correspond to open cell foam rubber, polymer fibers and polymer sealants (e.g., silicone) Acoustical damping may also be achieved through the use of acoustical insulation (e.g. foam) in cuff 20 which covers all or a portion of pump 51 and tubing 55. Other means of acoustical dampening of pump 51 and/or tubing 55 may include noise cancellation generators known in the art which may be controlled by controller 60. In various embodiments, device 10 can be configured such that loudness of the inflation of expandable 40 by pump 51 or other pressure source 50 is less than about 40 decibels; more preferably, less than about 30 decibels; still more preferably less than about 20 decibels and still more preferably less than about 10 decibels.

[0059] According to one or more embodiments, the pressure source 50 may be connected directly to the balloon 40 or other expandable member 40. Direct connection in this case may include any connector tubing 55. In additional or alternative embodiments, balloon or other expandable member 40 may be indirectly connected to the pressure source by means of a valve 56 fluidically coupled to at least one of the pressure source 50 or the expandable member 40. The valve 56 is configured and positioned so as to control the pressure released from the pressure source 50 to the balloon or other expandable member 40. Typically, the valve 56 will be positioned between the pressure source 50 and the expandable member 40 but may be positioned in other locations as well relative to these elements. In other embodiments, valve 56 may be integral to either the pressure source or the balloon or both.

[0060] In various embodiments, valve 56 may correspond to one or more control valves known in the art including various electronically controlled valves 57 including, for example, a solenoid valve. For the latter embodiments, the valve 56 my operatively coupled to the controller 60 such that the controller is able to send and receive signals so to open the valve according to specific time sequence and or based on pressure measurements. In the latter embodiments, the device 10 can also include a pressure sensor 58 that is fluidically coupled to one or more of the pressure source 50 and/or the expandable member 40 and operatively coupled to the controller 60 so as to send signals corresponding to measured pressure to the controller. The pressure sensor 58 may correspond to various electronic and or solid-state pressure sensors known in the art.

[0061] The controller 60 is configured to control inflation of the expandable balloon or other expandable member by controlling one more of the pressure source and/or embodiments of the control valve described herein. According to various embodiments, the controller is configured to control inflation of the expandable member 40 so as to produce a selected pressure cycle and/or compression regimen described herein. In many embodiments, this can be achieved through the use of a module 61 (typically a software module) which contains an algorithmic set of electronic instructions for preforming these tasks. Modules 61 may also include a pump drive module 64 and valve drive module 65 for controlling the generation of pressure and subsequent inflation of balloon 40. The controller 60 will typically correspond to a microprocessor, which may be of the shelf or incorporated into an ASIC. In other cases, the controller may correspond to a hardware device which may correspond to various analogue devices including various state devices. Combinations of microprocessor and analogue device based controllers are also contemplated. In particular embodiments, controller 60 may correspond to a first controller 63 and a second controller 64 for performing different functions. For example, controller 63 may handle communication between device 10 and external device 110 via transmitter 95 while second controller 64 performs various measurements and control function relating to the inflation of balloon 40 and control of a pressure cycle 200 as well as power management functions (e.g., battery monitoring). In a particular embodiment, controller 63 may correspond to a Lillypad microcontroller board while second controller 64 may correspond to an electronic board 64 containing one or more circuits or devices for control and measurement functions including, for example, control of valve 56, measurement of inflation pressure by sensor 58 and monitoring and control of the charging of battery 90 by battery monitoring and charging circuit 91. Board 64 may also include or be operatively coupled to a user accessible on-off switch or button 66.

[0062] In many embodiments, the DVT prevention device 10 will also include an internal power source 90 for powering one more of the controller 60, pressure source 50 or other electronic device or component included in the DVT prevention device 10. Suitable power sources 90 include super capacitors and various electrochemical storage batteries, such as alkaline, lithium or lithium ion batteries, with other battery chemistries also contemplated. For battery powered embodiments the device 10 may include a battery monitoring circuit 91. The use of rechargeable batteries is also contemplated. In such embodiments device 10 may include battery monitoring circuit may also comprise a battery charging circuit as well. In these and related embodiments, the device may be configured to be plugged into an external electric power source for powering the device as well as recharging the batteries. In various embodiments, the external power may comprise a wall socket or a USB source. In these embodiments device 10 may include a USB charging port or charging port 93. In use, embodiments employing an external power source allow conservation of battery power as well as providing a means of recharging the batteries vs replacing them. For embodiments using a battery power source, the use of circuitry and/or algorithms for detecting and alerting the user to the state of battery charge are also contemplated.

[0063] In many embodiments, the DVT prevention device 10 will also include a transmitter 95 for wireless communicating with an external device, a network or the cloud. Typically, the transmitter will comprise a miniature RF transmitter 95 and will be operatively coupled to at least controller. The RF other transmitter 96 is further configured to send and receive signals from an external device such as cell phone, tablet device or other like device so as to allow the DVT device including the controller to wirelessly communicate with theses external devices. The RF transmitter 95 can be connected or integral to the controller. Typically, the transmitter and/or controller will be configured to communicate via BLUETOOTH protocol but other wireless protocols known in the art area also contemplated. For BLUETOOTH embodiments, the transmitter 95 may comprise a BLUETOOTH transponder 96 known in the art. In use, such wireless communication ability allows the user or physician to do one more of the following: 1) custom program the DVT device for an individual user (e.g., a particular pressure cycle); 2) receive data on device performance (e.g. # of pressure cycles implemented, pressure generated, compression hold times, battery life data); 3) share the data with others (e.g., medical practitioners) over the cloud or other network; and 4) reprogram the device as needed depending upon the data or change in the patient's or mobility status. For example, in the latter case the device can be specifically programed with unique compression regimen for long trips on the airplane where the user will be seated for extended periods of time (e.g. 3 to 14 hours).

[0064] In alternative or additional embodiments, the DVT prevention device 10 may also include one more of push buttons 66 and the like, a display 67 and audio alarm 68 one or more of which may be coupled to the controller 60 and in particular embodiments to controller 64. The push buttons 66 can be configured to allow the user to do one more of the following: 1) turn the device on and/off; 2) select or adjust a compression regimen and/or pressure cycle; and 3) select or adjust pressure levels. The display 67 can display various information including the pressure level being used, information on a pressure cycle (e.g., graph of pressure vs time, the particular cycle/pressure regimen selected and/or being implemented and the time remaining in the cycle) and information on battery life. In various embodiments, the display 67 can be a touch screen allowing the user to enter information and/or otherwise interact with the device to perform various functions such as those described for the push buttons. The audio alarm 68 can be configured to alert the user to various events and/or information including for example, the start or end of a pressure cycle, interruption of a pressure cycle, and alarms about battery charge/battery life. Still other information and events are also contemplated for alert by alarm 68. In various embodiments, the controller can also be configured to send information on alarm event to the external device and/or over the cloud which create an audio alarm on the external device and/or to medical practitioner monitoring over the cloud.

[0065] Various embodiments of the invention also provide a system 100 for preventing deep vein thrombosis (DVT) comprising an embodiment of the DVT prevention device 10 described herein and an external device 150 such as cell, table device or the like configured to communicate with DVT prevention device as is show in FIG. 1. In many embodiments, the external device 100 and the DVT device 10 will be configured to communicate with each other using a BLUETOOTH communication protocol and in such embodiments each device will include a BLUETOOTH transponder known in the art. Typically, device 150 will have a display 160 and may also have one or more buttons or switches or other user activated actuators 155.

[0066] The external device 150 will typically include a software module (not shown) for displaying and/or wirelessly adjusting one or more parameters of the balloon inflation process including for example, set balloon inflation pressure, actual balloon inflation pressure, balloon inflation time, interval between inflations, and time remaining on a current balloon inflation or an inflation cycle described herein as well as related parameters and metrics. The can be accomplished by means of buttons or switches 155 which may be real or virtual (e.g., acccessable through display 160). The display 160 of the external device 150 may also be configured to allow the user to select, display or wirelessly change one or more of the above or other parameters used by the DVT device. Thus in use, the software module on the external device 150 functions as a chimeric application allowing the patient or medical practitioner to wirelessly display and control various parameter and metrics of the DVT device.

[0067] Various methods of using embodiments of the deep vein prevention device 10 for preventing deep vein thrombosis and related embolic events such as pulmonary embolic events (PEE) will now be described. In one embodiment, the method comprises placing an embodiment of the DVT prevention device 10 described herein around a patient's limb such as the leg where there is risk of developing a DVT due to poor circulation. In particular embodiments, the device is placed around the patient's knee so as to compressive one or more of the popliteal, femoral or tibial veins. The device may be pulled over the knee or wrapped around the knee. Then, the balloon or other expansion device is expanded according to a pressure cycle or compression regimen.

[0068] One embodiment of such a pressure cycle or compression regimen 200 depicted in FIG. 5A, comprises periods 210 of intermittent balloon inflation and application of compressive forces to tissue under the leg (herein force application period 220), followed by a holding period 220 of balloon inflation and applied compression force (herein compressive hold period 220) and then a relaxation period 230 corresponding to balloon deflation and no or minimal compressive force as shown in FIGS. 5A and 6A. The internment inflation compressive force application period 210 may, in some embodiments, correspond to a series of compressive pulses 215 (corresponding to balloon inflation) with intervals of relaxation 217 (corresponding to balloon deflation) between them as is shown in FIGS. 5A, 5C,5D and 6A. In the embodiments of pressure cycle 200 depicted in FIGS. 5A and 6A, sequential pressure pulses 215 are numbered 1, 2, 3, 4, 5 and the compressive hold period 220 is indicated by the horizontal line extending from the points A to point B. The corresponding increase in venous blood velocity (e.g., that of the common femoral vein) after each pressure pulse 215 is indicated by points, 1, 2, 3, 4 and 5 in FIGS. 5B and 6B. The corresponding increase from the compressive hold period 23 is shown in FIGS. 5B and 6B by the increase velocity going from points A to B. The end of the compressive hold period 230 is indicated by the point C in FIGS. 5A and 5B. The baseline venous blood velocity is indicated by point VB in FIGS. 5A and 5B. The increase in the venous velocity baseline after the completion of a pressure cycle 200 is also indicated by the point C in FIG. 5A.

[0069] In various embodiments, compressive pulses 215 (also described herein as pressure pulses or force pulses) may be in the form of square wave as shown in FIG. 5C or sine waves as shown in FIG. 5D with other shapes contemplated as well such as saw tooth. In additional or alternative embodiments, the pulse amplitude of pulse 215 can be sequentially increased (or decreased) in a selected manner (e.g., linear, geometric, first order, second order, etc.) so as to optimize the resulting increase in the blood velocity in the selected compressed vein(s). One or more of the timing, sequence, number, form (i.e., waveform) or other characteristic of compressive pulses 215 may be controlled by controller 60, for example, through use of pump drive module 64 and/or valve drive module 65 or other module 61.

[0070] Also, in additional or alternative embodiments, compressive pulses 215 may be synchronized or counter-synchronized to the user's heartbeat. Such embodiments can be implemented through a pulse detection means operably coupled to controller 60. Example pulse detection means may include without limitation pulse oximetry devices, acoustic sensing devices and EKG sensing devices known in the art.

[0071] The cycle 200 including compressive pulses 215, compressive hold period 220 and relaxation period 230 can be repeated multiple times (e.g. 2, 3, 4, 5 etc.) over a selected time period. As shown in FIGS. 5b and 6b, femoral blood velocity increases immediately above baseline with the first compressive pulse 215 and steadily increases with each subsequent compressive pulse 215 (e.g., pulse numbers 1, 2, 3, 4, 5 etc.) as well as continuing to increase after the hold period 220 reaching a new base line velocity at point C. In FIG. 6b, which depicts the venous blood velocity for an actual patient, the increase in blood velocity above baseline VB after the first pulse 215 was dramatic, nearly a three-fold increase and then continued with each subsequent compressive pulse resulting in a six-fold increase at the beginning of the hold period 230 (indicated by point A) and an eight fold increase at the end of the hold period (indicated by point B).

[0072] As shown in the examples section, use of such pressure cycles 200 on test subjects resulted in an average increase in peak blood velocity in the common femoral vein of between about 388 to 506% depending on whether the test subject was sitting with their knee bent or in a recombinant position with their knee straight. The largest increases were obtained after the pressure hold period 220. After completion of the cycle, the baseline peak velocities remained elevated for periods from 5 to 60 minutes, with two particular individual base line levels staying elevate for 15 and 60 minutes respectively, thus, demonstrating the long-term effect of a cycle 200 in maintaining elevated levels of venous circulation in the tissue region of the leg or other limb compressed by the applanator. Such long term increases in venous blood velocity result in the prevention of a DVT in the effected veins as wells as the prevention of pulmonary embolism caused by a DVT or related thrombotic event. In some embodiments, the cycle 200 may only include the series of compressive force pulses 215 with intervals of relaxation 217 between them. As shown in the examples section, such cycles resulted in increases in peak vein velocity in a range from 281 to 483%.

[0073] A discussion will now be presented of the values for the cycle parameters discussed above (e.g., pulse duration, etc.). In various embodiments, the number of compressive pulses 215 may be in the range of about 2 to 20 with specific embodiments of 4, 5, 10, 12, 15 and 20. In the embodiments described in the examples five pressure pulses were used and resulted in increases in peak vein velocity in range from 281 to 483%. An increased number of pulses may be used to obtain higher subsequent blood velocities. Also, pressure pulses 215 may have a selected duration 216, for example, in the range from about 1 to 20 seconds with specific embodiments of 5, 10 and 15 seconds. Longer durations are also contemplated. The interval of relaxation 217 between pulses can be in the range of about 1 to 20 seconds with specific embodiments of 5, 10 and 15 seconds. Longer durations are also contemplated. The compressive hold period 220 can in a range from about 30 seconds to five minutes, with specific embodiments of 1, 2, 3 and 4 minutes, with even longer periods contemplated. As discussed, herein one or more of the above parameters can be adjusted for an individual patient depending upon one or more of their age, weight, prior history of deep vein thrombosis, anticoagulation treatment (e.g., type and amount of a given drug dosage such as ZARELTO, WARFARIN, etc.) and various hemodynamic parameters (e.g., average blood velocity for a selected vein, peak vein blood velocity, blood pressure and pulse). In particular embodiments, one or more of the above parameters can be using ultrasonic imaging and doppler blood velocity measurement approaches described in the examples section and/or known in the art. In this way, the patient is able to obtain an optimized or otherwise improved response in use of the device to increase venous blood velocity and flow in a treated area and in turn, reduce the risk of DVT. Further, these parameters may be adjusted by the user or physician in response to changes in one or more of the patient's physical condition, activity level or medications (e.g. anti-coagulants or blood pressure medication) using an embodiment of the external device described herein. In related embodiments, they may be adjusted based on a duration the patient expects to be in a sitting position with limited mobility (e.g., such as on an airplane flight, train ride, etc.) so as to prevent the occurrence of a DVT during that period.

[0074] In other aspects of the invention, embodiments of the DVT prevention device can be used to increase venous blood velocity and flow so as produce one or more other physiologic benefits. Such benefits (in addition to DVT and associated PE prevention) may include, for example, increased venous return, increased cardiac output or reduced lactic acid and/or CO.sub.2 levels (in a leg, arm or other limb or tissue site compressed by embodiments of device 10). In particular embodiments, device 10 and pressure regimen 200 can be adapted to increase venous blood velocity and flow so as to increase venous return for patients suffering from venous insufficiency. In other embodiments, device 10 and pressure regimen 200 can be adapted to increase venous blood velocity and flow so as to increase cardiac output for patients suffering from one or more forms of heart failure in particular, left heart failure. Since under the Frank Starling Mechanism (known to those skilled in the cardiovascular physiology) increases in venous return result in equivalent or near equivalent increases in cardiac output (due to, inter alia, increases in ventricular fill volumes) embodiments of device 10 and the pressure regimen can be used to produce increases in cardiac output corresponding to the increase in venous blood flow produced by device 10 and a particular pressure cycle 200. In particular embodiments, cardiac output monitoring methods and instrumentation known in the art may be used to develop correlations between increased vein blood velocity and increases in cardiac output. These correlations may then be used to adjust the increase in vein blood velocity produced by a pressure cycle to yield a desired amount of increase in cardia output.

[0075] In particular embodiments, a patient in need of increased cardiac out (e.g. those suffering from left ventricular heart failure) may use device 10 to undergo multiple pressure cycles over the course of a day to maintain their cardiac output at a desired level (e.g., 5 liters minute). They may do so by wearing device 10 continuously or may put on device at set intervals (e.g., once an hour, two hours etc.) in order to undergo a desired number of pressure cycle. They may also wear more than once device 10, e.g., one on each leg to produce an enhanced increase in venous return and resulting increase in cardiac output. This approach may also allow for a reduced number of pressure cycles to be performed over the day.

[0076] Embodiments of device 10 and regimen 200 can also be configured to produce one or more of the above physiologic benefits so as to provide for improved exercise performance, for example by increasing cardiac output and/or reducing build up of lactic acid and/or CO.sub.2 levels in muscle being exercised. The improved exercise performance may include improved performance in running, swimming, weightlifting or other aerobic or anaerobic exercise. In particular embodiments, pressure regimen 200 can be adapted to produce amounts of increased venous velocity and blood flow tailored for improved performance in a selected exercise or activity, such as running or biking. Particular metrics of exercise performance such as VO.sub.2max, and various blood gas measurements (e.g., PCO2, PO2, PH, and HCO3, etc.) can be used to tune or fine tune pressure cycle 200 so as to optimize or otherwise increase user performance in a given exercise (e.g., running, biking, swimming weightlifting, etc.) and at given intensity level and period of exercise (sprint vs longer distance). The optimized pressure cycle 200 for a given exercise and exercise duration can then be stored in memory on controller 60 (e.g., in form of a module 61) or memory resources coupled to the controller. In one or more methods for using device 10 to enhance performance in a given exercise, a user may put on one or more devices 10 (e.g., on a leg or arm), select a particular pressure cycle 200 and undergo one or more pressure cycles 10 at selected time period before a given exercise (e.g., running). In some embodiments the user may wear device 10 and undergo one or more pressure cycles 200 while they are exercising so as to maintain enhanced venous blood while they are exercising. They may also keep device 10 on a selected time period after the exercise is completed or put it on afterwards so as to maintain the increased venous blood flow post exercise. In use, such embodiments serve to decrease the levels of metabolites in tissue post exercise which cause muscle soreness and fatigue. This in turn, reduces muscle recovery time from exercise in particular intense anaerobic exercise such as sprinting, weightlifting or prolonged aerobic exercise such as long distance running, biking swimming etc.

EXAMPLES

[0077] Various embodiments of the invention will now be further illustrated with reference to the following examples. However, it will be appreciated that these examples are presented for purposes of illustration and the invention is not to be limited by these specific examples or the details therein.

[0078] Experimental Design: To demonstrate that embodiments of the DVT device improved the efficiency of peripheral and central venous return and was on par with predicate devices, a brief study was performed to evaluate the amount of increase in peripheral and central venous velocity using an embodiment of the DVT prevention device. Five healthy adult volunteers without a history of DVT or Pulmonary Embolism were selected for the study.

[0079] Study Protocol: The study protocol was as follows. First, the superficial, deep, and common femoral vein was imaged with the volunteers in a sitting and semi-recumbent positions. In the semi recombinant position, the subject's knee was straight, their leg extended and their trunk was upright. In the sitting position, the subject's knee was bent. The baseline peak common femoral vein blood velocity was measured. Second, the popliteal vein was imaged and demonstrated to be compressible with the ultrasound probe to prove that there was no DVT within the popliteal vein at the time of the experiment. Third, the device was placed on the volunteer and under live ultrasound imaging, occlusion of the popliteal vein by the device was demonstrated. Fourth, the ultrasound probe was placed on the common femoral vein and peak common femoral vein blood velocity was measured during the device cycle. The device was allowed to then cycle though five compressive pulse periods followed by a holding period of compressive force as described above. Fifth, the device was turned off and after 5 minutes, peak common femoral vein blood velocity was measured using doppler ultrasound.

[0080] Results

[0081] The results of the study are shown in Tables 1 and 2 with the subject in a semi recombinant position with their knee straight (Table 1) or a sitting position with their knee bent (Table 2). The results for either position were dramatic and unexpected. For the straight knee semi-recumbent position, the device demonstrated an approximately 388% average increase in peak common femoral blood vein velocities (PCVV) after device pulsing and an approximately average 484% increase in peak common femoral blood vein velocities after the back pressure development phase of the cycle. For the bent knee sitting position, the device demonstrated an approximately average 387% augmentation in peak common femoral blood vein velocities (PCFVV) after device pulsing and an approximately a 506% average augmentation in peak common femoral blood vein velocities after the back pressure development phase of the cycle. Also, after completion of a cycle, the baseline PCFVV's remained elevated for extended periods of time e.g., from 15 to 60 minutes demonstrated the long term effect of the device and procedure in maintaining elevated velocities in the common femoral vein.

TABLE-US-00001 TABLE 1 Knee Straight, Volunteer in Semi-recumbent position Baseline PCFVV- PCFVV After PCFVV After Straight Knee Device Pulsing Device Hold Volunteer 1 5.6 cm/sec  .1 cm/sec  .5 cm/sec Volunteer 2 5.3 cm/sec 25.3 cm/sec 28.2 cm/sec Volunteer 3 6.9 cm/sec 26.9 cm/sec 36.2 cm/sec Volunteer 4 5.7 cm/sec 27.2 cm/sec 36.1 cm/sec Volunteer 5 9.6 cm/sec   27 cm/sec 34.1 cm/sec Average 25.7 32.02

TABLE-US-00002 TABLE 2 Knee Bent, Volunteer Sitting Baseline PCFVV- PCFVV After PCFVV After Bent Knee Device Pulsing Device Hold Volunteer 1 5.2 cm/sec 20.9 cm/sec 30.1 cm/sec Volunteer 2 4.9 cm/sec 22.1 cm/sec 29.2 cm/sec Volunteer 3 6.7 cm/sec 25.3 cm/sec 34.2 cm/sec Volunteer 4 5.4 cm/sec 26.1 cm/sec 32.1 cm/sec Volunteer 5 9.1 cm/sec 26.6 cm/sec 32.9 cm/sec Average 6.26 24.2

[0082] The foregoing description of various embodiments of the invention has been presented for purposes of illustration and description. It is not intended to limit the invention to the precise forms disclosed. Many modifications, variations and refinements will be apparent to practitioners skilled in the art. For example, various embodiments of the DVT prevention device can be adapted for appendages other than the legs including the arms. They may also be sized and otherwise adapted for various pediatric applications. Further, they may be adapted to allow the user sit, lie down or stand. Further still, they may be adapted to allow the user to be ambulatory. This includes engaging in various ambulatory activities including walking, running or biking and like actives. This also includes various exercises on devices which simulate one or more of these activities such as various elliptical exercise machines. In these and related embodiments, the cuff can be configured to have increased flexibility to allow the user to readily bend and flex their knee. Additionally, embodiments of the DVT prevention device can be used and/or adapted to increase venous blood so as produce one or more other physiologic benefits (in addition to DVT or PE prevention) including, for example, increased venous return, increased cardiac output, reduced lactic acid buildup and/or CO.sub.2 levels in a leg, arm or other limb or tissue site so compressed by embodiments of the DVT prevention device 10. One or more of these benefits may be selected to improve the users performance in an exercise or activity such as walking, running, swimming or biking.

[0083] Elements, characteristics, or acts from one embodiment can be readily recombined or substituted with one or more elements, characteristics or acts from other embodiments to form numerous additional embodiments within the scope of the invention. Moreover, elements that are shown or described as being combined with other elements, can, in various embodiments, exist as standalone elements. Further, embodiments of the invention specifically contemplate the exclusion of an element, act, or characteristic, etc. when that element, act or characteristic is positively recited. Hence, the scope of the present invention is not limited to the specifics of the described embodiments, but is instead limited solely by the appended claims.